Live Evaluations
Platinum Dermatology Advanced Therapeutic Update: June 25, 2024
About
Platinum Dermatology Advanced Therapeutic Update CME Session
Tuesday, June 25, 2024
8 PM ET / 5 PM PT
Part I: Medical Foods - Innovations and Applications in Clinical and Aesthetic Dermatology
Part II: Approaches to Acne Treatment Using Laser, Light & Energy Devices
Learning Objectives
At the completion of this activity, participants should be better able to:
Evaluate the advantages and disadvantages of using Photodynamic Therapy to treat acne
Review the safety and benefits of Laser and Light devices to treat acne
Distinguish the category of medical foods as an FDA special approved category
Utilize specific medical foods in clinical and aesthetic dermatology to enhance the health and well-being of our patients.
Intended Audience
Faculty
Mitchel Goldman, MD, FAAD
Cosmetic Laser Dermatology
Medical Director, Platinum Dermatology Partners
San Diego, California
Mark Nestor, MD, PhD
Director of Center for Clinical and Cosmetic Research
Voluntary Professor, Dermatology
University of Miami, Miller School of Medicine
Miami, FL
Anthony Petelin, MD
Platinum Dermatology Partners
Scottsdale, Arizona
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: Accure, Biofrontera
Shareholder: Accure
Grant/Research Support: Accure, Biofrontera
Advisory Board: Algeness, AMP Biologics, Castle Biosciences, Eirion Therapeutics Inc., Ferndale, Galderma, HTL Research, Hugel America, Ipsen, Novaestiq Corp, Primus Pharmaceuticals, RVL Pharmaceuticals, Sensus Healthcare, Sirnaomics
Grant/Research Support: Castle Biosciences, CROMA Pharma GmbH, Dermata Therapeutics, Eirion Therapeutics Inc., Fudan-Zhangjiang Co. Ltd., Galderma, Incyte corp., Jetema Co., Krystal Biotech, Mediwound, Merz Pharma, Mino Labs, Sirnaomics, Suneval Medical, Sun Pharma, Veradermics Inc.
Consultant: Aerolase, AMP Biologics, Benev Co. Inc., CROMA Pharma GmbH, Dermsquared, Eirion Therapeutics Inc., Emblation / Sarosa, HTL Research, Ipsen, Mediwound, Novaestiq Corp, Primus Pharmaceuticals, Revian, Sensus Healthcare, Sirnaomics, Sofwave, Vial
Speakers/ Bureau or Honoraria: Sensus Healthcare
No relevant financial relationships with any Ineligible Company in the past 24 months
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.